Enhanced Oral Bioavailability of Efavirenz by Solid Lipid Nanoparticles: In Vitro Drug Release and Pharmacokinetics Studies

Table 5

Physical characterization of SLN after stability studies.

Formulation code	Days	Characterization parameters
		Size (nm)		PDI		𝜁 potential (mV)		EE (%)
		4°C	25°C	4°C	25°C	4°C	25°C	4°C	25°C
ESLN-0	0th	362±2.1	362±2.1	0.455	0.455	−22.1	−22.1	46.28±1.5	46.28±1.05
	30th	390±1.4	398±2.4	0.456	0.482	−21.9	−21.1	46.21±1.3	42.87±2.6
	90th	406±1.7	428±2.7	0.479	0.502	−21.7	−20.9	45.59±1.27	38.92±1.3
	180th	449±1.1	534±1.9	0.491	0.563	−21.5	−20.6	43.13±1.9	34.28±1.8
ESLN-1	0th	267±2.2	267±2.2	0.334	0.334	−19.3	−19.3	70.2±0.98	70.2±0.98
	30th	301±1.6	316±2.2	0.334	0.349	−19.1	−19.1	69.6±0.4	68.8±1.5
	90th	342±2.1	372±2.2	0.352	0.389	−19.1	−18.7	69.2±1.3	67.3±1.2
	180th	347±1.3	427±2.2	0.394	0.421	−19.1	−18.4	67.1±1.4	65.6±0.92
ESLN-2	0th	213.4±2.4	213.4±2.4	0.315	0.315	−17.7	−17.7	76.1±0.7	76.1±0.7
	30th	221±1.1	234±0.97	0.316	0.318	−17.7	−17.2	75.7±0.91	74.5±1.2
	90th	236±1.6	278±1.2	0.317	0.327	−17.2	−17.1	75.2±1.4	73.3±0.9
	180th	278±2.2	302±1.3	0.319	0.334	−17.1	−17.1	73.6±1.2	72.6±2.1
ESLN-3	0th	124.5±3.2	124.5±3.2	0.234	0.234	−15.9	−15.9	86±1.2	86±1.03
	30th	124.5±1.1	124.8±2.8	0.234	0.235	−15.7	−15.7	85.7±1.1	85.3±2.1
	90th	124.7±2.3	124.9±1.4	0.235	0.235	−15.7	−15.7	85.5±1.5	84.3±1.32
	180th	124.8±1.4	125.2±1.6	0.235	0.236	−15.5	−15.4	85.1±1.3	83.6±1.7

All data expressed as mean ± S.D.; 𝑛=3; 𝑃≤0.05.